Payment overview · 2025
General Payments
$128.95
6 reported records · 4 companies
Healthcare provider profile · identity verified
Jongjin Kim, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LA PALMA, CA · NPI 1356605836
Verified facts
What the public records show
CMS Open Payments records show Jongjin Kim, M.D. received $128.95 in general payments during 2025 across 6 reported records.
Aimmune Therapeutics, Inc. accounted for 52.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Flector, Shingrix, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Zenpep by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trelegy Ellipta by this doctor in 2024.
IBSA Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Flector as an associated drug or biological on 6755 records involving 4085 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Flector by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $67.14 | 52.1% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.16 | 17.2% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $21.91 | 17.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.74 | 13.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $128.95 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $67.14 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $21.91 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.74 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 43 | exact normalized | Medicare Part D |
| Flector flector |
2025 | Flector | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 47 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
43 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
47 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| IBSA Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | Flector open payments reported associated product |
CMS Open Payments — General Payments 6755 supporting records · 4085 recipient NPIs · example record 1211687357 |
Flector · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1198 | 334 |
| Amlodipine Besylate | Amlodipine Besylate | 629 | 164 |
| Losartan Potassium | Losartan Potassium | 602 | 141 |
| Metformin Hcl | Metformin Hcl | 537 | 135 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 345 | 91 |
| Tamsulosin Hcl | Tamsulosin Hcl | 256 | 61 |
| Omeprazole | Omeprazole | 216 | 69 |
| Finasteride | Finasteride | 187 | 42 |
| Azithromycin | Azithromycin | 174 | 126 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 174 | 41 |
| Creon | Lipase/Protease/Amylase | 171 | 43 |
| Vascepa | Icosapent Ethyl | 171 | 31 |
| Alendronate Sodium | Alendronate Sodium | 161 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 160 | 48 |
| Jardiance | Empagliflozin | 145 | 22 |
| Levothyroxine Sodium | Levothyroxine Sodium | 140 | 38 |
| Glimepiride | Glimepiride | 137 | 31 |
| Celecoxib | Celecoxib | 124 | 42 |
| Metformin Hcl Er | Metformin Hcl | 112 | 29 |
| Ibuprofen | Ibuprofen | 111 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 109 | 33 |
| Lidocaine | Lidocaine | 105 | 19 |
| Januvia | Sitagliptin Phosphate | 98 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 96 | 25 |
| Simvastatin | Simvastatin | 95 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 95 | 49 |
| Pioglitazone Hcl | Pioglitazone Hcl | 88 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 35 |
| Lisinopril | Lisinopril | 85 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 15 |
| Gabapentin | Gabapentin | 70 | 26 |
| Myrbetriq | Mirabegron | 66 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 65 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 63 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 13 |
| Glipizide | Glipizide | 59 | 19 |
| Tradjenta | Linagliptin | 58 | 11 |
| Allopurinol | Allopurinol | 56 | 16 |
| Alprazolam | Alprazolam | 51 | 20 |
| Telmisartan | Telmisartan | 51 | 18 |
| Linzess | Linaclotide | 50 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 48 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 48 | 11 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Meloxicam | Meloxicam | 47 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 47 | 32 |
| Montelukast Sodium | Montelukast Sodium | 46 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 46 | 13 |
| Minoxidil | Minoxidil | 45 | 14 |
| Diclofenac Epolamine | Diclofenac Epolamine | 44 | suppressed |
| Ozempic | Semaglutide | 44 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 43 | 43 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 30 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 42 | 28 |
| Ezetimibe | Ezetimibe | 42 | 11 |
| Glipizide Er | Glipizide | 41 | 12 |
| Ketoconazole | Ketoconazole | 40 | 16 |
| Acyclovir | Acyclovir | 38 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Carvedilol | Carvedilol | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Sucralfate | Sucralfate | 33 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 24 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Famotidine | Famotidine | 31 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 29 |
| Ciclopirox | Ciclopirox | 30 | suppressed |
| Loperamide | Loperamide Hcl | 30 | 11 |
| Tramadol Hcl | Tramadol Hcl | 30 | 13 |
| Flector | Diclofenac Epolamine | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 21 |
| Azelastine Hcl | Azelastine Hcl | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | 14 |
| Desmopressin Acetate | Desmopressin Acetate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Benzonatate | Benzonatate | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | 15 |
| Tadalafil | Tadalafil | 22 | suppressed |
| Clotrimazole | Clotrimazole | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Prednisone | Prednisone | 20 | 15 |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Eliquis | Apixaban | 17 | suppressed |
| Furosemide | Furosemide | 17 | suppressed |
| Memantine Hcl | Memantine Hcl | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Prolia | Denosumab | 17 | 14 |
| Rybelsus | Semaglutide | 17 | suppressed |
| Acarbose | Acarbose | 16 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Mirtazapine | Mirtazapine | 15 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Repatha Pushtronex | Evolocumab | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 13 | suppressed |
| Miglitol | Miglitol | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 12 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $128.95 · 6 records | Aimmune Therapeutics, Inc. | AREXVY, CAPVAXIVE, Flector, GARDASIL 9, Licart, SHINGRIX, Tirosint, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error